Momentum Plays: Edgewise and Ericsson Hit 52-Week Highs Amid Sector Shifts
Edgewise Therapeutics and Ericsson have both breached 52-week price peaks, signaling robust investor confidence in biotech innovation and telecom infrastructure recovery. While Edgewise benefits from clinical momentum in muscle disease treatments, Ericsson's ascent reflects a stabilized global 5G landscape and a strategic pivot toward AI-native networking.